The Satiety and Clinical Adiposity Liraglutide Evidence (SCALE) Phase III trial in non-diabetic and diabetic people investigated the safety and efficacy of liraglutide 3.0 mg (once daily subcutaneous injections)
In the cohort of 165,860 AKD patients who could withdraw from acute dialysis, the mean age was 59.0 years, and 49.7% were male
To date, GLP-1R has been identified presynaptically on GABAergic nerve terminals ( ex vivo dopaminergic neurotransmission in the amygdala and striatum ( Another aspect that should be explored is the treatment effect in female rodents
Con 30 mg, 1 ml da 30 mg/ml
Wegovy doesnt carry the same explicit warning at the standard 2.4 mg dose, but the way the medications work is similar, so any woman of reproductive age starting a GLP-1 medication should speak to her GP about contraception options
Large-scale, controlled studies are needed before any conclusions can be drawn